On April 1, the Shanxi Provincial Pharmaceutical equipment centralized bidding procurement network issued a "Notice on Announcing the Revocation of Platform-Linked Procurement Qualifications of Some Enterprises", which means that a number of pharmaceutical companies are ready to withdraw from the "Collection and Procurement Bureau".
According to the Notice, a total of 42 pharmaceutical manufacturers and 77 pharmaceutical product regulations have applied for the withdrawal of the network. According to the regulations, after the withdrawal of the network, these products will not be able to hang the net again in Shanxi Province in the next two years.
Among the enterprises that applied for withdrawal from the network, there are many well-known foreign companies such as GlaxoSmithKline, Wyeth, Johnson & Johnson, Gilead, Novartis, Allergan, Merck& undone, as well as domestic enterprises such as Qilu, Taiji, Yabao, Lei Yunshang, Yulin Pharmaceutical, and Sichuan Good Doctor. Both Chinese and Western medicines are included.
Since the middle of 2021, a large number of pharmaceutical companies have taken the initiative to withdraw from the network in Hunan, Heilongjiang and other regions, especially involving a large number of traditional Chinese medicine varieties. It deserves attention.
Traditional Chinese medicine: enjoying policy preferences goes hand in hand with the withdrawal of the network
Chinese medicine has been encouraged by Chinese medicine for the past two years, and in early 2022, the development prospects of Chinese medicine have been affirmed under the "preference" of the policy.
On March 29, the General Office of the State Council triggered the "14th Five-Year Plan for the Development of Traditional Chinese Medicine", which clarified the goals, tasks and key measures for the development of traditional Chinese medicine during the "14th Five-Year Plan" period, and the Chinese medicine industry ushered in a major positive. But this still can't stop the resistance of Chinese medicine companies to the collection.
In the varieties of Shanxi net removal this time, Beijing Tongrentang has a total of three products, namely Zhibai Dihuang Pill (360 pills /bottle), Liuwei Dihuang Pill (360 pills/bottle) and Yufeng Ningxin Tablet (100 tablets/bottle). In 2021, Beijing Tongrentang achieved revenue of 14.603 billion yuan, up 13.86% year-on-year. Among them, Liuwei Dihuang Pill ranked among the top five in Tongrentang's revenue.
In addition, Lei Yunshang Pharmaceutical Group Co., Ltd., a famous Chinese medicine expert in Shanghai and controlled by China Yuanda, also withdrew the hanging net of four products, namely bitter yellow granules (10 bags/box), Liushen Pills (90 capsules/box, 120 capsules/box) and Luoshu liver capsules (40 capsules/box).
In addition to regional famous brands, Chinese medicine injections also have players who withdraw nets. For example, safflower injection, which is commonly used for the treatment of cardiovascular and cerebrovascular diseases, shows that Yabao Pharmaceutical Group Co., Ltd. and Langham Group Wanrong Pharmaceutical Co., Ltd. have chosen to withdraw their safflower injections.
Brand proprietary Chinese medicines have a good market reputation and have a tendency to "consumerize". If you are bargained in the collection, you will face a very embarrassing situation. Instead of staying in the hospital channel and waiting to be bargained, it is better to exit and rely entirely on the retail market. This seems to have become the unanimous choice of brand Chinese medicine enterprises such as Tongrentang and Lei Yunshang.
Giant anti-cancer drugs are also withdrawing from the network queue
In addition to traditional Chinese medicine, the Western medicines of many well-known pharmaceutical companies have also waved away from the "collection".
Some of these medicines are prepared for daily household use. For example, Hainan Huluwa Pharmaceutical's Omeprazole enteric-coated capsules (28 capsules/box) for the treatment of gastrointestinal discomfort, digestive system drugs are one of the three major sectors of Hainan Huluwa Pharmaceutical's revenue, in the first half of 2021, the digestive system drugs achieved revenue of 141 million yuan, accounting for 22.35% of the total revenue of the current period.
In addition to daily medication, the anti-cancer drugs of some well-known pharmaceutical companies have also issued a "re-network" signal.
For example, Qilu Pharmaceutical's four-specification commonly used anti-cancer drug ticio tablets applied for withdrawal from the network. In March 2019, Qilu Pharmaceutical's oral drug Tigio Capsules was the first product in China to pass the consistency evaluation, ranking among the billion varieties under Qilu.
International players are also "discouraged" from collecting. According to the Notice, GlaxoSmithKline's lapatinib toluene sulfonate tablets (Teresa), which are mainly used for the treatment of breast cancer, applied to be withdrawn from the network in Shanxi.
The drug was originally developed by GlaxoSmithKline, which was approved by the FDA in 2007 and entered the Chinese market in 2013. At its peak, its global sales were close to $4 million. With the end of the patent period, many domestic pharmaceutical companies have opened imitations, such as Hengrui Pharmaceutical and Kelun Pharmaceutical.
Collection has been implemented for nearly 5 years, in the domestic market with high pressure on drug prices and fierce competition, whether it is domestic pharmaceutical companies or foreign pharmaceutical companies, traditional Chinese medicine or Western medicine, enterprises and categories that cannot guarantee high cost performance will gradually withdraw from this competition.
#Liuwei Dihuang Pills ##Collection ##挂网 #